Home » From Omics to Clinics - Using New Technologies to Advance Diagnosis and Treatment of Hematologic Malignancies

From Omics to Clinics - Using New Technologies to Advance Diagnosis and Treatment of Hematologic Malignancies

Jointly sponsored by The Leukemia & Lymphoma Society (LLS),

Funding provided by LLS, and supported by educational grants from Celgene Corporation and Millennium: The Takeda Oncology Company.

Specialty: Hematology/Oncology

Valid through: March 18, 2015

Target Audience:

This activity has been designed to meet the educational needs of hematologists, oncologists, and other healthcare professionals who have an interest in the study and treatment of hematologic malignancies.

Program Overview:

Genomic and other omics-based technologies offer great promise for improved diagnosis and treatment of hematologic malignancies. Within the past decade, the knowledge and tools derived from the completed sequencing of the human genome have transformed the diagnosis and classification of hematologic malignancies.

Aided by the rapid advances in genomic science and sequencing capabilities, cancer researchers are currently working toward the goal of making genomic profiling a part of patient care when appropriate. As omics become increasingly more accessible in clinical medicine, new ethical, legal, and social issues arise.

In order to improve patient outcomes, healthcare professionals who treat patients with hematologic malignancies should be well informed about the potential applications of omics to research and disease management.

Education/Learning Objectives

After completing this activity, the participant should be better able to:

Applying Next Generation Sequencing Technologies to Hematologic Malignancies –
The Next Era - Module 1
Elaine R. Mardis, PhD
Education Objectives:

Describe next generation methodologies for cancer genome sequencing
Apply principles of genome sequencing to determine clonal evolution patterns in acute myeloid leukemia (AML) patients with relapse
Outline a plan for AML next generation sequencing in clinical practice

Genomic Approaches to Target Aberrant Transcription in Leukemia - Module 2
Kimberly Stegmaier, MD
Education Objectives:

Identify challenges in targeting aberrant transcription
Summarize novel omic approaches for discovering new therapeutic targets and small molecule therapies
Evaluate differentiation therapy as an alternative approach to acute myeloid leukemia (AML) treatment

Therapeutic Strategies in Lymphoma from Functional and Structural Genomics - Module 3
Louis M. Staudt, MD, PhD
Education Objectives:

Outline important signaling pathways in the pathogenesis of activated B-cell (ABC) diffuse large B-cell lymphoma (DLBCL)
Summarize clinical trial data for B-cell receptor blockade with Ibrutinib in patients with ABC DLBCL
Describe potential novel synergistic combination therapies for ABC DLBCL

Functional Genomic Approaches for Delivery of Personalized, Targeted Therapies - Module 4
Jeffrey W. Tyner, PhD
Education Objectives:

Describe the elements necessary for developing personalized targeted therapy
Explain functional screening processes used to determine potential therapeutic targets in leukemia patients
Outline an algorithm for integrating functional and genomic data to improve patient outcomes

Genomic Testing in Clinical Practice -
Privacy, Ethical and Legal Considerations and Ethics and Informatics Informed Consent for Cancer Research in the 21st Century: It's Complicated and Panel Discussion and Q & A - Module 5
Samuel L. Volchenboum, MD, PhD, MS
Eric Kodish, MD
Education Objectives:

List the factors to consider when discussing genomic testing with patients
Summarize the benefits and challenges of genetic screening in children and adults
Apply the American College of Medical Genetics and Genomics recommendations for reporting incidental findings in clinical genome sequencing
List prerequisites and communications steps for informed consent in genomic testing
Outline a model for obtaining clinical trial informed consent from parents of children with leukemia
Describe the implications of the Learning Health Care System on patient care

Faculty

Cheryl L. Willman, MD
The Maurice and Marguerite Liberman Distinguished Chair in Cancer Research
Professor of Pathology and Internal Medicine
Director & CEO
University of New Mexico Cancer Center
University of New Mexico School of Medicine
Albuquerque, NM

Elaine R. Mardis, PhD
Professor of Genetics and Molecular Microbiology
Co-Director, The Genome Institute at Washington University
Washington University School of Medicine
St. Louis, MO

Kimberly Stegmaier, MD
Associate Professor of Pediatrics
Harvard Medical School
Dana-Farber Cancer Institute
Boston Children's Hospital, Broad Institute
Boston, MA

Louis M. Staudt, MD, PHD
Director
Center for Cancer Genomics
National Cancer Institute
Bethesda, MD

Jeffrey W. Tyner, PhD
Assistant Professor
Oregon Health & Science University
Portland, OR

Samuel L. Volchenboum, MD, PhD, MS
Assistant Professor of Pediatrics and Computation
Director, Center for Research Informatics
The University of Chicago Medicine
Comer Children's Hospital
Chicago, IL

Eric Kodish, MD
F.J. O'Neill Professor and Chairman, Department of Bioethics
Director, Center for Ethics, Humanities and Spiritual Care
Cleveland Clinic
Cleveland, OH

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of The Leukemia & Lymphoma Society (LLS), Postgraduate Institute for Medicine, and RMEI, LLC. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

Module 1:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only

Module 2:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This is by completing all modules.

Module 3:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This is by completing all modules.

Module 4:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This is by completing all modules.

Module 5:
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This is by completing all modules.

Disclosure Of Conflicts Of Interest

Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

Name of Faculty or Presenter		Reported Financial Interest
Cheryl L. Willman, MD		Has no affiliations with commercial interests to disclose.
Elaine R. Mardis, PhD		Consulting Fees (e.g., advisory boards): Pacific Biosciences Fees for Non-CME Services Received Directly from a Commercial Interest or their Agents (e.g., speakers' bureau): Illumina Ownership Interest (stocks, stock options or other ownership interest excluding diversified mutual funds): Life Technologies
Kimberly Stegmaier, MD		Has no affiliations with commercial interests to disclose.
Louis M. Staudt, MD, PhD		Has no affiliations with commercial interests to disclose.
Jeffrey W. Tyner, PhD		Contracted Research: Constellation Pharmaceuticals, Ventana Medical Systems, Inc.
Samuel L. Volchenboum, MD, PhD, MS		Has no affiliations with commercial interests to disclose.
Eric Kodish, MD		Has no affiliations with commercial interests to disclose.

The following LLS planners, Louis J. DeGennaro, PhD, Clare Karten, MS, and Richard C. Winneker, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity.

The following RMEI, LLC planner and manager, Cynthia M. Kunzer, CMP, hereby states that she or her spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interests related to the content of this CME activity.

The following PIM planners and managers, Laura Excell, ND, NP, MS, MA, LPC, NCC, Trace Hutchison, PharmD, Samantha Mattiucci, PharmD, CCMEP, and Jan Schultz, RN, MSN, CCMEP, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past

Disclosure Of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

This program consists of 6 continuing education activites.

Module 1 — Applying Next Generation Sequencing Technologies to Hematologic Malignancies – The Next Era

0.75 AMA PRA Category 1™ Credit Hours

Module 2 — enomic Approaches to Target Aberrant Transcription in Leukemia

0.5 AMA PRA Category 1™ Credit Hours

Module 3 — Therapeutic Strategies in Lymphoma from Functional and Structural Genomics

0.75 AMA PRA Category 1™ Credit Hours

Module 4 — Functional Genomic Approaches for Delivery of Personalized, Targeted Therapies

0.5 AMA PRA Category 1™ Credit Hours

Module 5 — Genomic Testing in Clinical Practice - Privacy, Ethical and Legal Considerations and Ethics and Informatics Informed Consent for Cancer Research in the 21st Century: It's Complicated

1.25 AMA PRA Category 1™ Credit Hours